Tango Therapeutics (NASDAQ:TNGX) vs. Syndax Pharmaceuticals (NASDAQ:SNDX) Head-To-Head Survey

Tango Therapeutics (NASDAQ:TNGX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Valuation and Earnings

This table compares Tango Therapeutics and Syndax Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38 million	67.36	-$101.59 million	($0.85)	-29.32
Syndax Pharmaceuticals	$172.35 million	9.36	-$285.42 million	($2.51)	-7.25

Tango Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Tango Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Tango Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.

Insider & Institutional Ownership

79.0% of Tango Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Tango Therapeutics and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Tango Therapeutics and Syndax Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1	2	13	0	2.75
Syndax Pharmaceuticals	1	0	10	0	2.82

Tango Therapeutics presently has a consensus target price of $43.46, indicating a potential upside of 74.40%. Syndax Pharmaceuticals has a consensus target price of $42.30, indicating a potential upside of 132.42%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Tango Therapeutics.

Summary

Tango Therapeutics beats Syndax Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

About Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.